cCAM Biotherapeutics is a startup, most recent round Acquired, 1 tracked investor.
cCAM Biotherapeutics is a startup. cCAM Biotherapeutics has been acquired. Brouky records 1 investor associated with the company.
cCAM Biotherapeutics develops immunotherapies for cancer, including CM-24, an immunomodulatory antibody that blocks a novel immune checkpoint to enhance the immune system's ability to attack tumors. The company was acquired by Merck in July 2015.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.